Cacipliq 20® – Foot Ulcer
Efficacy of a New Heparan Sulfate Mimetic Dressing in the Healing of Foot and Lower
Extremity Ulcerations in Type 2 Diabetes: A Case Series
Nikolaos Papanas, Costas Demetzos, Natassa Pippa, Efstratios Maltezos and Nicholas Tentolouris
A novel heparan sulfate glycosaminoglycan mimetic product for local application to promote wound healing (Cacipliq 20) has recently become available.
It is a biophysical therapeutic product comprising a polysaccharide as an innovative biomaterial to accomplish mechanical tissue engineering and skin regeneration in the site of ulceration.
We present a series of 12 patients with type 2 diabetes (4 men and 8 women; age 53-87 years; diabetes duration 8-25 years) having chronic resistance to therapy for foot and lower extremity ulcerations.
Cacipliq 20 was locally applied twice per week after careful debridement. Complete ulcer healing was accomplished in all patients after a mean treatment duration of 4.92 months (range = 2-12 months). The product was very well tolerated.
In conclusion, these results, although preliminary, are encouraging and suggest adequate efficacy and safety of the new product in difficult-to-heal foot and lower extremity ulcerations in type 2 diabetes.